STOCK MARKET BSE NSE

Man given first dose as Phase-I human clinical trial of Covaxin begins at AIIMS

In the second phase, 750 people will be recruited between 12-65 years, AIIMS Director Dr Randeep Guleria had said.

Published: 24th July 2020 08:58 PM  |   Last Updated: 25th July 2020 08:02 AM   |  A+A-

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.  (Photo | Special Arrangement)

Express News Service

NEW DELHI: The All India Institute of Medical Sciences Delhi on Friday conducted the first trial ofCovaxin, India’s indigenous vaccine candidate against coronavirus. The vaccine was administered to a 30-year-old man who had volunteered for the trial run. “Two volunteers were called for Friday’s trial out of which one came today and the other will be injected on Saturday.

The person, after injecting the drug, was monitored for two hours. After showing no symptoms or no signs of side-effects, he was sent back home,” said Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS. The volunteer was first screened before the trial three days ago and given the first dose of 0.5 ml intramuscular injection around 1.30 pm.

“The person will be monitored for a week through telephone. We will keep taking updates from him about his health and how he is behaving. We have also given him a diary which has all necessary steps that need to be followed,” said the senior doctor.

According to him, 20 more volunteers have been screened so far whose reports are awaited. Depending upon the health condition of these volunteers, they will be administered the vaccine in the coming days. Earlier this week, AIIMS Director Dr Randeep Guleria had said the trial would be conducted in three phases for which 1,125 samples were collected.

The phase-I trials will be conducted on healthy people aged 18-55 years who have no comorbidity. As many as 375 people were selected for the first phase. In the second phase, 750 people between 12-65 years will be studied.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp